N@N

Obagi Medical Products to Present at Two Investor Conferences in February and March

_{//health-fitness.news-articles.net/content/2009/ .. -investor-conferences-in-february-and-march.html}
^{Published in Health and Fitness on Thursday, February 12th 2009 at 4:23 GMT, Last Modified on 2009-02-12 04:24:11 by Market Wire}  

LONG BEACH, Calif.--([ BUSINESS WIRE ])--Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today that Company management will present a corporate overview at the following two investor conferences:

• The Roth 21^st Annual Orange County Growth Stock Conference to be held on February 16-18 at the Ritz Carlton Laguna Niguel in Dana Point, CA. The presentation will take place at 8:30 a.m. (PST) on Tuesday, February 17, 2009.
• The Stanford Group Company 14^th Annual Healthcare Conference to be held on March 5-6 at The Four Seasons Hotel in Washington, D.C. The presentation will take place at 1:00 p.m. (PST) on Thursday, March 5, 2009.

A live webcast of both presentations will be available via the internet by visiting the Investor Relations section of the Company's web site at [ www.obagi.com ]. The archived presentation will be available on the web site for 30 days.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics™ technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm®, 1988; Obagi-C® Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi® Professional-C (a line of highly stable vitamin C serums), 2005; Obagi® Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm™ eye treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm® M.D. Systems for normal to dry skin, June 2007; Obagi ELASTIderm™ Décolletage System, January 2008; SoluCLENZ Rx Gel for acne treatment in the pharmacy channel in August 2008; and the Obagi® Rosaclear™ System for Rosacea in January 2009. Visit [ www.obagi.com ] for more information.